Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
· 30 patients with active or chronic active antibody mediated rejection (AMR) episodes post kidney transplantation have been enrolled and randomized 2:1 to imlifidase v.s. standard-of-care · Completion of enrollment marks an important milestone for Hansa, as the company explores the potential of imlifidase in the post transplantation setting. · Acute AMR episodes post kidney transplantation occur in 5-7% of patients, with significant risk of patients losing graft function. There is no approved treatment for preventing and treating AMR.Lund, Sweden May 23, 2022. Hansa Biopharma AB, “